SG Americas Securities LLC Increases Stock Position in CryoPort, Inc. $CYRX

SG Americas Securities LLC raised its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 663.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,280 shares of the company’s stock after acquiring an additional 110,602 shares during the period. SG Americas Securities LLC’s holdings in CryoPort were worth $1,207,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CYRX. Nisa Investment Advisors LLC increased its holdings in CryoPort by 299.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the period. ProShare Advisors LLC purchased a new position in shares of CryoPort during the second quarter worth $75,000. Avanza Fonder AB grew its stake in shares of CryoPort by 31.4% in the second quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after buying an additional 2,601 shares in the last quarter. Finally, PharVision Advisers LLC purchased a new stake in shares of CryoPort in the 2nd quarter valued at $82,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the sale, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. This trade represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

CryoPort Price Performance

CYRX stock opened at $11.03 on Friday. The business’s 50-day moving average is $9.59 and its two-hundred day moving average is $9.07. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The firm has a market capitalization of $552.26 million, a P/E ratio of 9.43 and a beta of 1.54. CryoPort, Inc. has a 1 year low of $4.58 and a 1 year high of $11.44.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $44.23 million for the quarter, compared to analyst estimates of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. Analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CYRX has been the subject of several research reports. Needham & Company LLC lifted their target price on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. UBS Group raised their price objective on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.83.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.